શરેખાન

#CiplaLtd covered in today's Stock of the day podcast. Cipla is a global pharmaceutical company with a geographically diversified presence and products registered in more than 170 countries. Cipla banks on its branded business in India and South Africa, both of which together… https://t.co/bHbqbYhaTy #CiplaLtd

Experience the insightful 3R Podcast! Tune in now to gain valuable long-term views from Sharekhan's experts on #PunjabNationalBank, #DLFLtd, #CiplaLtd, #ChaletHotelsLtd. Watch now - https://youtu.be/O_h_RFkqNEs?si=oUkaYV9L8BJUoz8jDisclaimer - http://rb.gy/14y35#Sharekhan #Podcast #StockAnalysis #SharekhanPodcast #SharekhanKar #StockToBuyNow #PunjabNationalBank #DLFLtd #CiplaLtd #ChaletHotelsLtd #Sharekhan #Podcast #StockAnalysis #SharekhanPodcast #SharekhanKar #StockToBuyNow

Start your trading week with insightful Sharekhan's 3R research podcast. Watch Now - https://youtu.be/yjUw5b85Z80Disclaimer - http://rb.gy/14y35#Sharekhan #Podcast #stockmarkets #IndianHotelsCompany #MarutiSuzuki #CiplaLtd #RelianceIndustries #Sharekhan #Podcast #stockmarkets #IndianHotelsCompany #MarutiSuzuki #CiplaLtd #RelianceIndustries

Stock Market opportunities rarely knock twice. Don’t miss out due to inaction! 📊 Check our 3R Research ACTIONABLE UPDATES, now in audio avatar: https://www.youtube.com/watch?v=1EBOt7iepY0Today, we cover: 🎯 #Thermax 🎯 #Cipla 🎯 #LumaxAutotechnologies #Sharekhan #SharekhanKar #Thermax #Cipla #LumaxAutotechnologies #Sharekhan #SharekhanKar

#SharekhanResearch retains Buy rating on #Cipla (12month PT Rs 1150) adjusting for one offs #Q4FY22 was operational… https://t.co/NNrztNTBvb #SharekhanResearch #Cipla #Q4FY22

#SharekhanResearch retains Buy rating on #Cipla (PT Rs 1150) #Q3FY22 was mixed qtr, results ahead of est, strng gwt… https://t.co/7w4OwWoUI3 #SharekhanResearch #Cipla #Q3FY22

#SharekhanFNA #SharekhanResearch retain Buy rating on #Cipla (PT Rs 1150) #Q2FY22 healthy qtr, results ahead of est… https://t.co/DanXyypUgt #SharekhanFNA #SharekhanResearch #Cipla #Q2FY22

#SharekhanResearch retains Buy rating on #Cipla (PT Rs 1150) #Q1FY22 strng qtr, results beat estimates; strengtheni… https://t.co/08yhJtou3s #SharekhanResearch #Cipla #Q1FY22

#SharekhanFNA #SharekhanResearch retains buy recommendation on #Cipla (PT revised to Rs 950); India business to be… https://t.co/V2iymuPsfu #SharekhanFNA #SharekhanResearch #Cipla